432 related articles for article (PubMed ID: 34503220)
1. Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives.
Roviello G; Catalano M; Santi R; Palmieri VE; Vannini G; Galli IC; Buttitta E; Villari D; Rossi V; Nesi G
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503220
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
4. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
5. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.
Aurilio G; Cimadamore A; Lopez-Beltran A; Scarpelli M; Massari F; Verri E; Cheng L; Santoni M; Montironi R
Transl Androl Urol; 2021 Mar; 10(3):1521-1529. PubMed ID: 33850786
[TBL] [Abstract][Full Text] [Related]
6. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Cheng W; Fu D; Xu F; Zhang Z
Oncogenesis; 2018 Jan; 7(1):2. PubMed ID: 29358573
[TBL] [Abstract][Full Text] [Related]
7. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
8. A review of avelumab in locally advanced and metastatic bladder cancer.
Rao A; Patel MR
Ther Adv Urol; 2019; 11():1756287218823485. PubMed ID: 30728859
[TBL] [Abstract][Full Text] [Related]
9. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
11. Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.
Sanguedolce F; Falagario UG; Zanelli M; Palicelli A; Zizzo M; Busetto GM; Cormio A; Carrieri G; Cormio L
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673455
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
13. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.
Gupta S; Gill D; Poole A; Agarwal N
Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134806
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
[TBL] [Abstract][Full Text] [Related]
15. Immunobiology and immunotherapy in genitourinary malignancies.
Tsiatas M; Grivas P
Ann Transl Med; 2016 Jul; 4(14):270. PubMed ID: 27563657
[TBL] [Abstract][Full Text] [Related]
16. New immunotherapy treatments in non-muscle invasive bladder cancer.
Califano G; Ouzaid I; Verze P; Stivalet N; Hermieu JF; Xylinas E
Arch Esp Urol; 2020 Dec; 73(10):945-953. PubMed ID: 33269713
[TBL] [Abstract][Full Text] [Related]
17. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
19. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
Loriot Y; Rouprêt M
Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]